preterm infants in hospital fed human milk to supplementation or no supplementation with additional protein. Two reviewers independently abstracted data, assessed trial quality and the quality of evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE).
LOW PLGF AND ULTRASOUND DEFINED FETAL GROWTH RESTRICTION IN LATE-ONSET SMALL-FOR-GESTATIONAL AGE PREGNANCIES
Background: Detailed Doppler monitoring in small-for-gestational-age (SGA) pregnancies requires resources not always available. We investigated whether low PlGF at diagnosis of SGA identifies the same fetuses subsequently classified growth restricted (FGR) by detailed Doppler studies, plus the association between low PlGF and adverse outcomes.
Methods: Using an historical database of normotensive SGA pregnancies (fetal abdominal circumference <10th%centile) ≥32 weeks gestation from Auckland, New Zealand (1993 -1997 , we classified 'initial FGR' as an abnormal umbilical artery resistance index (RI) or estimated fetal weight <3rd customised centile at SGA diagnosis. The ability of low PlGF (<5th%ile) to identify 'secondary FGR' (abnormal internal carotid RI, cerebroplacental ratio and/or mean uterine artery RI) was calculated. Within the whole cohort, adverse perinatal outcomes and hypertensive disease were compared by PlGF status.
Results: Among 136 pregnancies, 56 (41.1%) had initial FGR. Of the remaining, 20 (25.0%) had secondary FGR, and 17 (21.3%) had low PlGF. The sensitivity of low PlGF identifying secondary FGR was 0.30 (95% CI 0.14-0.50), specificity 0. Background: Limited data exists on high frequency jet ventilation (HFJV) for improving respiratory outcomes in preterm infants. Our objective was to assess if high frequency jet ventilation (HFJV) is associated with reduced odds of death or discharge home on oxygen in preterm infants.
Methods: A case control study (1/2/2010-1/6/2014) comparing the primary outcome as 'death or discharge home on oxygen' in preterm infants who needed HFJV (Cases) versus those who did not (Controls). Controls were matched to cases (1:1) on gestation, birthweight, gender, place of birth, growth status, antenatal glucocorticoids, and dexamethasone as treatment for severe bronchopulmonary dysplasia. Logistic regression analysis was used to control for confounders.
Results: Data on all preterm infants who needed HFJV (Cases: n=50) and 50 controls during the study period was analysed. Primary outcome was more frequent in cases vs. controls, but not significant after adjusting for mean airway pressure and adjuvant therapy (e.g. diuretics) Conclusions: HFJV was not associated with reduced odds of death or discharge home on oxygen in preterm infants in our study. Adequately powered randomised trials are required to assess the efficacy of HFJV in reducing the risk of death or discharge home on oxygen in preterm infants. 
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